Daily Pharma Scoop 2017-09-22: VanEck Vectors Biotech ETF, Esperion’s growth potential, Pfizer’s EU Approval
- The VanEck Vectors Biotech ETF is discussed.
- Esperion’s potential in the statin-intolerant anti-cholesterol market is discussed.
- Pfizer’s BAVENCIO (avelumab) is approved in Europe for the treatment of adult patients with metastatic Merkel cell carcinoma.
Avisol Capital Partners, managed by Drs Udaya Maiya and Ashok Dutta, is writing a daily scoop of all sorts of news, catalysts, ratings, and other actionable details for its watch list stocks (and the rest of the healthcare universe). The watch list is available to Total Pharma Tracker subscribers. Some sections, like the catalyst data, abstract selections, AdComm coverages, Buy/Sell summaries etc are also available to subscribers only. This is an abridged version; for the entire Pharma Scoop, please subscribe to our Marketplace service.
Our daily analysis of a stock/ETF with a major event/upside: VanEck Vectors Biotech ETF
The full unabridged post can be accessed, on SeekingAlpha Marketplace.